CYAD | Celyad Oncology SA Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.4700 - 0.5280
52 Week Range	0.1500 - 3.07
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	48,998
Average Volume	18,057
Shares Outstanding	30,294,600
Market Cap	14,238,462
Sector	Healthcare
Industry	Biotechnology
IPO Date	2015-06-19

Valuation
Profitability
Growth
Health
P/E Ratio	-0.32
Forward P/E Ratio	N/A
EPS	-1.47
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	35
Country	Belgium
Website	CYAD

Celyad Oncology is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno Oncology, Cardiology, and Medical devices. Its main product candidates include CAR-T and C-Cure. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CATH and C-CATHez and CARDIO 3 BIOSCIENCES. The firm has Cardiology and Immuno-oncology operating segments.

CYAD's peers: ADXN, APM, IMRN, IPHA

*Chart delayed

Analyzing fundamentals for CYAD we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see CYAD Fundamentals page.

Watching at CYAD technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on CYAD Technicals page.